Neuromodulation for reducing neurogenic detrusor overactivity in spinal cord injury

Investigating transcutaneous neuromodulation for reduction of bladder, bowel and spasticity in spinal cord injury as an alternative to pharmacological treatment: towards wearable devices

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN99373118

Enrollment

Registered

2017-07-07

Start date

2016-04-04

Completion date

Unknown

Last updated

2020-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Specialty: Renal disorders, Primary sub-specialty: Renal disorders Urological and Genital Diseases Renal disorders

Interventions

To ascertain the most effective transcutaneous stimulation site the efficacy of neuromodulation using surface electrodes is investigated at distinct anatomical sites: Dorsal Genital Nerve, Posterior T

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Spinal Cord Injured 2. Aged 18-70 3. Male or Female 4. Injury sustained >6 months ago 5. Urodynamically proven Neurogenic Detrusor Overactivity

Exclusion criteria

Exclusion criteria: 1. Recipient of intra-detrusor botulinum toxin injections within the last 6 months 2. Previous surgical intervention on bladder/sphincters 3. Showing positive leucocytes and nitrites on urinalysis on the day of investigation 4. Pregnancy

Design outcomes

Primary

Measure	Time frame
Bladder overactivity is measured using standard urodynamics to measure bladder pressures and volumes without stimulation present (control), then with stimulation over one of four sites (experimental).	—

Secondary

Measure	Time frame
No secondary outcome measures	—

Countries

United Kingdom

Contacts

Public ContactSean Doherty

sean.doherty.15@ucl.ac.uk+44 (0)207 909 5605

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026